Agenus Revenue 2010-2022 | AGEN
Agenus revenue from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Agenus Annual Revenue
(Millions of US $) |
| 2021 |
$296 |
| 2020 |
$88 |
| 2019 |
$150 |
| 2018 |
$37 |
| 2017 |
$43 |
| 2016 |
$23 |
| 2015 |
$25 |
| 2014 |
$7 |
| 2013 |
$3 |
| 2012 |
$16 |
| 2011 |
$3 |
| 2010 |
$3 |
| 2009 |
$3 |
Agenus Quarterly Revenue
(Millions of US $) |
| 2022-09-30 |
$23 |
| 2022-06-30 |
$21 |
| 2022-03-31 |
$26 |
| 2021-12-31 |
$20 |
| 2021-09-30 |
$253 |
| 2021-06-30 |
$11 |
| 2021-03-31 |
$12 |
| 2020-12-31 |
$31 |
| 2020-09-30 |
$15 |
| 2020-06-30 |
$27 |
| 2020-03-31 |
$15 |
| 2019-12-31 |
$35 |
| 2019-09-30 |
$20 |
| 2019-06-30 |
$16 |
| 2019-03-31 |
$80 |
| 2018-12-31 |
$6 |
| 2018-09-30 |
$13 |
| 2018-06-30 |
$16 |
| 2018-03-31 |
$2 |
| 2017-12-31 |
$8 |
| 2017-09-30 |
$3 |
| 2017-06-30 |
$4 |
| 2017-03-31 |
$27 |
| 2016-12-31 |
$6 |
| 2016-09-30 |
$4 |
| 2016-06-30 |
$7 |
| 2016-03-31 |
$6 |
| 2015-12-31 |
$8 |
| 2015-09-30 |
$7 |
| 2015-06-30 |
$6 |
| 2015-03-31 |
$4 |
| 2014-12-31 |
$2 |
| 2014-09-30 |
$2 |
| 2014-06-30 |
$3 |
| 2014-03-31 |
$1 |
| 2013-12-31 |
$0 |
| 2013-09-30 |
$1 |
| 2013-06-30 |
$1 |
| 2013-03-31 |
$1 |
| 2012-12-31 |
$1 |
| 2012-09-30 |
$1 |
| 2012-06-30 |
$1 |
| 2012-03-31 |
$13 |
| 2011-12-31 |
$1 |
| 2011-09-30 |
$1 |
| 2011-06-30 |
$1 |
| 2011-03-31 |
$1 |
| 2010-12-31 |
$1 |
| 2010-09-30 |
$1 |
| 2010-06-30 |
$1 |
| 2010-03-31 |
$1 |
| 2009-12-31 |
$1 |
| 2009-09-30 |
$1 |
| 2009-06-30 |
$1 |
| 2009-03-31 |
$1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.777B |
$0.296B |
|
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
|
